Revolution Medicines (RVMD) COO Horn Sells $9.7M of Stock
Margaret Horn sold 60,400 shares of Revolution Medicines for $9.67 million on June 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Margaret Horn, Chief Operating Officer at Revolution Medicines, Inc. ($RVMD), sold 60,400 shares at an average price of $160.17, worth about $9.67 million, on June 15, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $RVMD is up 3.6% after 1 week, up 15.2% after 1 month and up 11.2% to date (from the $160.06 close on Jun 15, 2026).
RVMD
Revolution Medicines, Inc.
Key Points
- Margaret Horn, COO of Revolution Medicines, sold 60,400 shares on June 15, 2026, at $160.17 per share, totaling $9.67 million.
- Shares of Revolution Medicines traded near $156.58, with a market cap of $33.3 billion and a 52-week range of $34.00 to $166.50.
- Analysts from Evercore ISI Group and RBC Capital maintain a 'buy' rating, with price targets of $220 and $182 respectively, as of June 2026.
Get $RVMD trade alerts by text
We text you when insiders, Congress or big funds trade $RVMD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures
Margaret Horn, Chief Operating Officer of Revolution Medicines, Inc. (NasdaqGS: RVMD), sold 60,400 shares of the company on June 15, 2026. The shares were sold at an average price of $160.17, totaling approximately $9.67 million. This transaction was part of a planned sale.
Insider Buying and Selling at Revolution Medicines, Inc.
In addition to the June 15 transaction, Margaret Horn executed several trades on June 17, 2026. She sold another 29,600 shares at $160.12 and purchased the same amount at lower prices, part of her ongoing trading activities. These transactions were both planned and non-planned, indicating a mix of strategic and market-based decisions.
Other Institutional Activity in Revolution Medicines
Farallon Capital Management LLC reduced its position in Revolution Medicines by 978,000 shares, now holding 13,604,796 shares valued at about $1.32 billion. In contrast, BlackRock, Inc. increased its stake by 2,286,050 shares, bringing its total to 11,212,706 shares worth roughly $1.09 billion. Janus Henderson Group PLC decreased its holdings by 2,537,006 shares, resulting in 9,766,496 shares valued at approximately $949.54 million. Baker Bros. Advisors LP added 100,000 shares, ending with 9,555,357 shares valued at $929.26 million.
Revolution Medicines, Inc. Stock Down 18.0%
Shares of Revolution Medicines traded around $156.58. The company boasts a market cap of $33.3 billion. With a forward P/E ratio of -27.45, the stock reflects its current unprofitability. The beta is 1.407, indicating a higher volatility compared to the market. Revolution Medicines' stock has a 52-week low of $34.00 and a high of $166.50, with a 50-day moving average of $143.94 and a 200-day moving average of $93.97.
Analysts Set New Price Targets
On June 10, 2026, Evercore ISI Group maintained a 'buy' rating on Revolution Medicines with a price target of $220. RBC Capital also maintained a 'buy' rating on June 2, 2026, with a target of $182. Other firms like HC Wainwright & Co. and Oppenheimer reiterated their 'buy' ratings with targets of $195 each. The stock has a consensus 'strong buy' recommendation with an average target price of $187.29 from 21 analysts.
About Revolution Medicines
Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing targeted therapies for cancers driven by RAS mutations. The company’s pipeline includes RAS(ON) inhibitors and RAS companion inhibitors designed for precision oncology. Led by CEO Dr. Mark A. Goldsmith, Revolution Medicines employs around 883 people and is committed to advancing treatments for RAS-addicted cancers.
Bottom Line
Margaret Horn's recent stock sale is part of her planned trading activities, reflecting routine insider transactions. Revolution Medicines continues to be an active player in the biotechnology sector, with its stock experiencing significant institutional interest. Analysts remain optimistic, maintaining 'buy' ratings with high price targets, highlighting confidence in the company's future prospects.
Related Filing Alerts
Source: Margaret Horn's Form 4 filing on $RVMD (Jun 15, 2026). Find the original filing: RVMD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts